Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways

Area of Science:

• Neuroscience
• Cell Biology
• Genetics

Background:

• Alzheimer's disease (AD) involves beta-amyloid (Abeta) deposition, elevated caspase-3, and impaired cytochrome c oxidase.
• The cause of increased Abeta in sporadic AD remains unclear.
• Mitochondrial dysfunction is implicated in neurodegenerative diseases.

Purpose of the Study:

• To investigate the role of mitochondrial DNA from Alzheimer's disease (AD) subjects in Abeta production and deposition.
• To explore the link between mitochondrial dysfunction, oxidative stress, and Abeta secretion in sporadic AD.

Main Methods:

• Utilized cytoplasmic hybrid (cybrid) cells derived from mitochondrial DNA of nonfamilial AD patients.
• Measured Abeta secretion, intracellular Abeta levels, caspase-3 activity, and mitochondrial membrane potential (delta(psi)m).
• Assessed the effects of caspase-3 inhibition, secretase inhibition, and antioxidant treatment (S(-)pramipexole).

Main Results:

• AD cybrid cells exhibited reduced mitochondrial membrane potential (delta(psi)m) and increased Abeta(1-40)/Abeta(1-42) secretion.
• Elevated intracellular Abeta, cytoplasmic cytochrome c, and caspase-3 activity were observed in AD cybrids.
• Caspase-3 or secretase inhibition normalized Abeta secretion; S(-)pramipexole reduced it.
• Expression of AD mitochondrial genes induced oxidative stress and lowered delta(psi)m.

Conclusions:

• Mitochondrial dysfunction in sporadic AD drives oxidative stress and activates cell death pathways.
• Caspase-3 mediated Abeta peptide secretion contributes to increased Abeta deposition in the AD brain.
• Therapeutic strategies should focus on restoring mitochondrial function and reducing Abeta secretion.